HC Wainwright Issues Negative Estimate for Oculis Earnings

Oculis Holding AG (NASDAQ:OCS - Free Report) - Stock analysts at HC Wainwright lowered their Q2 2025 earnings estimates for Oculis in a report issued on Monday, May 12th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.47) for the quarter, down from their prior forecast of ($0.41). HC Wainwright currently has a "Buy" rating and a $32.00 target price on the stock. The consensus estimate for Oculis' current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Oculis' Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($2.20) EPS and FY2026 earnings at ($1.69) EPS.

Oculis (NASDAQ:OCS - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.26). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. The business had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.22 million.

A number of other research firms also recently issued reports on OCS. Robert W. Baird lifted their price objective on shares of Oculis from $37.00 to $41.00 and gave the stock an "outperform" rating in a report on Thursday, March 13th. Chardan Capital lifted their price objective on shares of Oculis from $28.00 to $33.00 and gave the stock a "buy" rating in a report on Friday, May 9th.

Oculis Stock Up 0.5%

OCS traded up $0.10 during mid-day trading on Wednesday, reaching $17.95. 2,030 shares of the stock were exchanged, compared to its average volume of 43,428. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The stock has a market capitalization of $783.51 million, a PE ratio of -9.22 and a beta of 0.27. The company has a 50 day moving average price of $17.94 and a two-hundred day moving average price of $18.42. Oculis has a 1 year low of $10.79 and a 1 year high of $23.08.

Institutional Trading of Oculis

Hedge funds have recently added to or reduced their stakes in the stock. Pivotal bioVenture Partners Investment Advisor LLC increased its holdings in Oculis by 32.4% in the 1st quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 2,300,774 shares of the company's stock worth $43,784,000 after acquiring an additional 563,078 shares during the last quarter. SR One Capital Management LP purchased a new position in Oculis during the first quarter valued at approximately $6,137,000. Aberdeen Group plc grew its stake in Oculis by 24.1% during the first quarter. Aberdeen Group plc now owns 1,253,119 shares of the company's stock valued at $23,847,000 after acquiring an additional 243,695 shares in the last quarter. abrdn plc grew its stake in Oculis by 23.0% during the fourth quarter. abrdn plc now owns 1,009,424 shares of the company's stock valued at $17,150,000 after acquiring an additional 188,871 shares in the last quarter. Finally, Alyeska Investment Group L.P. purchased a new position in Oculis during the first quarter valued at approximately $2,499,000. Institutional investors own 22.30% of the company's stock.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.